Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide) for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid; and in Phase 2 clinical trial for the treatment of Angelman and Pitt Hopkins. In addition, it develops NNZ-2591, which is in Preclinical trial stage for the treatment of Prader-Willi syndrome. The company was incorporated in 2001 and is based in Camberwell, Australia.
Metrics to compare | NEU | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNEUPeersSector | |
---|---|---|---|---|
P/E Ratio | 14.5x | −7.9x | −0.5x | |
PEG Ratio | −1.52 | −0.03 | 0.00 | |
Price/Book | 5.7x | 7.1x | 2.6x | |
Price / LTM Sales | 9.5x | 16.1x | 3.3x | |
Upside (Analyst Target) | 51.4% | 254.1% | 40.3% | |
Fair Value Upside | Unlock | −6.2% | 5.1% | Unlock |